Serum Folate Deficiency in Older People Associated With Heightened Dementia
|
By LabMedica International staff writers Posted on 21 Mar 2022 |

With ageing, serum concentrations of folate decrease, leading to a higher prevalence of a threshold-based medical condition termed serum folate deficiency. The highest folate deficiency rates in the population occur among older adults, with estimated prevalence rates ranging from 5% to 20%.
Evidence suggests that serum folate deficiency increases the likelihood of deficits in cognitive performance and neurological functioning. This positions serum folate as a possible biomarker to modify the risk of dementia. However, the few observational studies that have examined the association between serum folate deficiency and the risk of dementia have shown inconsistent results.
A team of mental health professionals led by those at the Icahn School of Medicine at Mount Sinai (New York, NY, USA) examined the associations between serum folate deficiency and the risks of incident dementia and all-cause mortality in a large national sample of older adults. A prospective cohort of 27,188 aged 60–75 years without pre-existing dementia for at least 10 years was tested for serum concentrations of folate and followed up for dementia or all-cause mortality. Serum folate deficiency was classified as present or absent.
Serum folate is a direct measure of vitamin B9 in the blood and may therefore function as a biomarker (i.e., an objectively measured indicator). Serum concentrations of folate were measured using chemiluminescent microparticle immunoassay technology and derived from the clinical biochemistry electronic health records (EHRs). Measurements were ascertained as needed based on clinical impressions of the treating physician from 1 January 2013 to 30 October 2017.
The team reported that 3,418 (just under 13%) participants were folate deficient, defined as levels below 4.4 ng/mL. Folate deficiency was associated with a substantially heightened risk of both dementia and death from any cause. Among those who were folate deficient, the incidence of dementia was estimated at 7.96/10,000 person years, while death from any cause was estimated at 19.2/10,000 person years. This compares with an estimated dementia incidence of 4.24 and of death from any cause of 5.36/10,000 person years among those who weren't folate deficient.
The authors concluded that serum concentrations of folate may function as a biomarker used to modify the risks of dementia and mortality in old age, adding that older adults should be routinely screened for folate deficiency. The implications for public health policy appear to be to reliably monitor serum concentrations of folate in older adults and treat deficiency for preventative measures and/or as part of implemented therapeutic strategies while regularly reviewing patients' clinical outcomes. The study was published on March 15, 2022 in the journal Evidence-Based Mental Health.
Related Links:
Icahn School of Medicine at Mount Sinai
Latest Clinical Chem. News
- Urine-Based Nanosensor Tracks Lung Cancer and Fibrosis Noninvasively
- FDA-Cleared Assay Enables Comprehensive Automated Testosterone Testing
- CE-Marked Blood Biomarker Test Advances Automated Alzheimer’s Diagnostics
- Blood-Based Alzheimer’s Test Gains CE Mark for Amyloid Pathology Detection
- Noninvasive Urine Test May Support Earlier Diagnosis of Psychiatric Disorders
- At-Home Blood and Cognitive Tests Support Dementia Risk Stratification
- Ultrasensitive Test Detects Key Biomarker of Frontotemporal Dementia Subtype
- Routine Blood Tests Years Before Pregnancy Could Identify Preeclampsia Risk
- Blood Test Detects Testicular Cancer Missed by Standard Markers
- Routine Blood Tests Identify Biomarkers Linked to PTSD
- Proteomic Data Underscore Need for Age-Specific Pediatric Reference Ranges
- Routine Blood Count Ratio Linked to Future Alzheimer’s and Dementia Risk
- Label-Free Microfluidic Device Enriches Tumor Cells and Clusters from Pleural Effusions
- Rapid Biosensor Detects Pancreatic Cancer Biomarker for Early Detection
- Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation
- Blood Test Predicts Alzheimer Disease Risk Before Imaging Changes and Symptoms
Channels
Molecular Diagnostics
view channel
Breast Cancer-Specific Signatures Link Genome Instability to Outcomes
Genomic instability is a hallmark of cancer, but most genomic analyses have relied on broad signatures shared across multiple malignancies, limiting their precision for individual tumor types.... Read more
Whole-Genome MRD Test Detects Early Recurrence in Muscle-Invasive Bladder Cancer
Bladder cancer is among the most common malignancies in the United States, with about 85,000 new cases each year. The muscle-invasive form accounts for roughly one quarter of diagnoses and carries a high... Read more
Blood Test Detects Early Nonresponse in Metastatic Prostate Cancer
Prostate cancer is the most common cancer in the U.K., with more than 64,000 men diagnosed and 12,000 deaths each year. For the roughly 10,000 men annually with advanced disease, early assessment of treatment... Read more
FDA-Cleared Genomic Profiling Assay Guides Treatment Selection in Solid Tumors
Datar Cancer Genetics (DCG; Nashik, India), a global precision oncology company, has announced that its tissue-based comprehensive genomic profiling (CGP) assay for all solid tumors, CellDx-Tissue, has received U.... Read moreHematology
view channel
Stem Cell Biomarkers May Guide Precision Treatment in Acute Myeloid Leukemia
Acute myeloid leukemia (AML) is an aggressive blood cancer that most often affects older adults and still carries a poor prognosis despite therapeutic advances. Venetoclax-based regimens have improved... Read more
Advanced CBC-Derived Indices Integrated into Hematology Platforms
Diatron, a STRATEC brand, has introduced six advanced hematological indices on its Aquila, Aquarius 3, and Abacus 5 hematology analyzers. The new Research Use Only (RUO) indices include Neutrophil-to-Lymphocyte... Read moreImmunology
view channel
Routine TB Screening Test May Reveal Immune Aging and Mortality Risk
Immune aging is associated with weaker responses to vaccination, greater risks of infection, and higher levels of inflammation. Leveraging routinely ordered laboratory tests to quantify that responsiveness... Read more
Biomarkers and Molecular Testing Advance Precision Allergy Care
Allergic diseases often present with similar symptoms but can be driven by distinct biological mechanisms, making standardized care inefficient for many patients. Historically, individuals with pollen... Read moreMicrobiology
view channel
Study Finds Hidden Mpox Infections May Drive Ongoing Spread
Mpox continues to circulate despite vaccination, and many cases show no known link to a symptomatic partner. The role of people without symptoms has remained uncertain, limiting clarity on how transmission persists.... Read more
Large-Scale Genomic Surveillance Tracks Resistant Bacteria Across European Hospitals
Antimicrobial resistance (AMR) poses a growing threat to patient safety, with carbapenem-resistant Enterobacterales causing difficult-to-treat infections and leaving clinicians with limited therapeutic options.... Read more
Molecular Urine and Stool Tests Do Not Improve Early TB Treatment in Hospitalized HIV Patients
Tuberculosis is the leading cause of death among people living with HIV, and diagnosis in hospital settings remains difficult. Symptoms are often non-specific, disease can be extrapulmonary, and many patients... Read morePathology
view channel
Rapid AI Tool Predicts Cancer Spatial Gene Expression from Pathology Images
Gene expression profiling can inform tumor biology and treatment selection, but spatial assays remain costly and time-consuming. Results can take weeks and cost thousands of dollars, limiting large-scale... Read more
AI Pathology Test Receives FDA Breakthrough for Bladder Cancer Risk Stratification
Non–muscle invasive bladder cancer has highly variable outcomes, complicating surveillance and treatment planning. Risk assessment typically relies on stage, grade, and tumor size, leaving uncertainty... Read moreTechnology
view channel
Point-of-Care Testing Enhances Health Literacy and Self-Management in Chronic Disease
Limited access to general practitioners and pathology services can delay diagnosis and monitoring for people in regional and remote communities. Rapid, on-the-spot testing can shorten turnaround times... Read more
Fully Automated Sample-to-Insight Workflow Advances Latent TB Testing
Latent tuberculosis remains a substantial testing workload for clinical laboratories as screening programs expand. Despite this growth, only about 40% of testing has shifted from traditional skin tests... Read moreIndustry
view channel
AI-Powered Multi-Functional Analyzer Wins German Innovation Award
Hematology services are increasingly delivered across distributed care settings, where limited staffing and complex workflows can extend turnaround times. Advanced morphology review still often depends... Read more








